Mundipharma obtains global ex-US rights to Zubsolv
30 June 2016 | By Victoria White, Digital Content Producer
Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence...
List view / Grid view
30 June 2016 | By Victoria White, Digital Content Producer
Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence...
22 April 2015 | By Victoria White
Orexo has announced data from a trial assessing the long-term safety and efficacy of Zubsolv sublingual tablet for the treatment of opioid dependence...